In this article, we will discuss Relugolix and Cardiac Electrophysiology. So, let’s get started.
Relugolix and Cardiac Electrophysiology
Cardiac Electrophysiology
In a randomized, double-blind, placebo- and positive-controlled (open-label moxifloxacin), parallel- group thorough QT/QTc study, no increase in mean QTc interval > 10 ms was identified after administration of single 60 or 360 mg doses of relugolix (0.2 or 1 times the recommended loading dose, respectively)